February 23, 2023 10:31 AM EST

Sickle cell R&D hit by three culls in one day at Novartis/Intellia, Sangamo and Graphite Bio

Kyle LaHucik

Senior Reporter

Three biotechs disclosed pullbacks on sickle cell disease R&D in the span of 16 hours: with Graphite Bio ending work, Sangamo Therapeutics searching for a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sickle cell R&D hit by three culls in one day at Novartis/Intellia, Sangamo and Graphite Bio

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Sick­le cell R&D hit by three culls in one day at No­var­tis/In­tel­lia, Sang­amo and Graphite Bio

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Sickle cell R&D hit by three culls in one day at Novartis/Intellia, Sangamo and Graphite Bio

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?